Status: Recruiting
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).
Participants needed: 100
Trial details
Phase: Phase 1Age: 12-75Biological sex: AllType: InterventionalSponsor: Jazz PharmaceuticalsUpdated: Jun 9, 2026Locations: 24
Eligibility criteria
Participant has a documented diagnosis of focal epilepsy according to the ILAE C... [+9]